Skip to main content
SpringerLink
Log in

The Current of Status of Fibronectin in Clinical Medical Practice

  • Chapter
Plasma Fractionation and Blood Transfusion

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 13))

  • 85 Accesses

Abstract

Fibronectin is a dimeric glycoprotein with a molecular weight of 400,000 to 440,000 daltons composed of two 220,000 dalton subunit chains linked by disulfide bridges. It participates in host defenses by acting as a nonspecific opsonin, capable of removing non-bacterial debris from blood including fibrinogen/fibrin complexes, collagenous debris, denatured proteins and remnants of cellular cytoskeleton. Such debris may occur after trauma, sepsis, burn injury, or disseminated intravascular coagulation (DIC). This material may also be passively infused in blood transfusions which contain microaggregate debris.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alitalo K, Hovi T, Vaheri A. Fibronectin is produced by human macrophages. J Exp Med 1980; 151: 602–13.

    Article  PubMed  CAS  Google Scholar 

  2. Bevilacqua Mp, Amrani D, Mosesson MW, Bianco C. Receptors for cold insoluble globulin (plasma fibronectin) on human monocytes. J Exp Med 1981; 153: 42–60.

    Article  PubMed  CAS  Google Scholar 

  3. Postlethwaite AE, Keski-Oja J, Balian G, Kang A. Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000 molecular weight non-gelatin-binding fragment. J Exp Med 1981; 153: 494–9.

    Article  PubMed  CAS  Google Scholar 

  4. Pommier CG, Inada S, Fries LF, Takahashi T, Frank MM, Brown EJ. Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med 1983; 157: 1844–54.

    Article  PubMed  CAS  Google Scholar 

  5. Bianco C. Fibrin, fibronectin and macrophages. Ann Ny Acad Sci 1983; 408: 602–9.

    Article  PubMed  CAS  Google Scholar 

  6. Mosher DF, Proctor RA. Binding and factor XHIa-mediated cross-linking of a 27 kilodalton fragment of fibronectin to Staphylococcus aureus. Science 1980; 209: 927–9.

    Article  PubMed  CAS  Google Scholar 

  7. Kuusela P. Fibronectin binds to Staphylococcus aureus. Nature 1978; 276: 718–20.

    Article  PubMed  CAS  Google Scholar 

  8. Van de Water L, Destree AT, Hynes RO. Fibronectin binds to some bacteria but does not promote their uptake by phagocytic cells. Science 1983; 220: 201–4.

    Article  PubMed  Google Scholar 

  9. Proctor RA, Prendergast E, Mosher DF. Fibronectin mediated attachment of Staphylococcus aureus to human neutrophils. Blood 1982; 59: 681–7.

    PubMed  CAS  Google Scholar 

  10. Lanser ME, Saba TM. Opsonic fibronectin is necessary for optimal serum-mediated phagocytosis of Staphylococcus aureus by human neutrophils. Adv Shock Res 1982; 8: 111.

    PubMed  CAS  Google Scholar 

  11. Lanser ME, Saba TM. Fibronectin as a co-factor necessary for optimal granulocyte phagocytosis of Staphylococcus aureus. J Reticuloendothel Soc 1981; 30: 415–24.

    PubMed  CAS  Google Scholar 

  12. Saba TM, Albert WH, Blumenstock FA, Evanega G, Staehler F, Cho E. Evaluation of rapid immunoturbidimetric assay for opsonic fibronectin in surgical and trauma patients. J Lab Clin Med 1981; 98: 482–91.

    PubMed  CAS  Google Scholar 

  13. Blumenstock FA, Saba TM, Weber P, Laffin R. Biochemical and immunological characterization of human opsonic SB glycoprotein: its identity with cold-insoluble globulin. J Biol Chem 1978; 253: 4287–91.

    PubMed  CAS  Google Scholar 

  14. Blumenstock FA, Saba TM, Roccario E, Cho E, Kaplan JE. Opsonic fibronectin after trauma and particle injection determined by a peritoneal macrophage monolayer assay. J Reticuloendothel Soc 1981; 30: 61–71.

    PubMed  CAS  Google Scholar 

  15. Saba TM, Gregory TJ, Blumenstock FA. Circulating immunoreactive and bioassayable opsonic plasma fibronectin during experimental tumor growth. Br J Cancer 1980; 41: 956–65.

    Article  PubMed  CAS  Google Scholar 

  16. Saba TM, Blumenstock FA, Shah DM, et al. Reversal of fibronectin and opsonic deficiency in patients. Ann Surg 1984; 199: 87–96.

    Article  PubMed  CAS  Google Scholar 

  17. Dillon BC, Estes JE, Saba TM, et al. Actin-induced reticuloendothelial phagocytic depression as mediated by its interaction with fibronectin. Experimental Pathol 1983; 38: 208–23.

    Article  CAS  Google Scholar 

  18. Snyder E, Barash P. Mosher DF, Walter SD. Plasma fibronectin level and clinical status in cardiac surgery patients. J Lab Clin Med 1983; 102: 881–9.

    PubMed  CAS  Google Scholar 

  19. Bowen M, Muller T. Influence of sample preparation on estimates of blood fibronectin concentration. J Clin Pathol 1981; 36: 233–5.

    Article  Google Scholar 

  20. Boughton BJ, Simpson A. Plasma fibronectin in acute leukemia. Brit J Haematol 1982; 51: 487–91.

    Article  CAS  Google Scholar 

  21. Norfolk DR, Bowen M, Roberts BE, Child JA. Plasma fibronectin in myeloproliferative disorders and chronic granulocytic leukaemia. Brit J Haematol 1983;55:319–24.,

    Article  CAS  Google Scholar 

  22. Choate JJ, Mosher DF. Fibronectin concentration in plasma of patients with breast cancer, colon cancer and acute leukemia. Cancer 1983; 51: 1142–7.

    Article  PubMed  CAS  Google Scholar 

  23. Mosher DF, Williams EM. Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation. J Lab Clin Med 1978; 91: 729–35.

    PubMed  CAS  Google Scholar 

  24. Brodin B, Lieden G, Malm C, Vikrot O. Plasma fibronectin deficiency during chemotherapy of acute myeloid leukemia. Scan J Haem 1983; 30: 247–9.

    Article  CAS  Google Scholar 

  25. Owens MR, Cimino CD. Synthesis of fibronectin by the isolated perfused rat liver. Blood 1982; 59: 1305–9.

    PubMed  CAS  Google Scholar 

  26. Perri RT, Kay NE, McCarthy J, Vessella RL, Jacobs HS, Furcht LT. Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity. Blood 1982; 60: 430–5.

    PubMed  CAS  Google Scholar 

  27. Gluud C, Dejgaard A, Clemmensen I. Plasma fibronectin concentrations in patients with liver diseases. Scand J Clin Lab Invest 1983; 43: 533–7.

    Article  PubMed  CAS  Google Scholar 

  28. Snyder EL, Ferri PM, Mosher DF. Fibronectin in liquid and frozen stored blood components. Transfusion 1984; 24: 53–6.

    Article  PubMed  CAS  Google Scholar 

  29. Saba TM. Reversal of plasma Fn deficiency in septic-injured patients by cryoprecipitate infusion. In: Massive Transfusion in Surgery and Trauma. Collins JA, Murawski K, Shafer AW eds. New York, A.R. Liss 1982: 129–150.

    Google Scholar 

  30. Annest SJ, Scovill WA, Blumenstock FA, et al.Increased creatinine clearance following cryoprecipitate infusion in trauma and surgical patients with decreased renal function. J Trauma 1980; 20: 726–32.

    Article  PubMed  CAS  Google Scholar 

  31. Scovill WA, Saba TM, Blumenstock FA, et al. Opsonic at surface binding glycoprotein therapy during sepsis. Ann Surg 1978; 188: 521–9.

    Article  PubMed  CAS  Google Scholar 

  32. Scovill WA, Annest SJ, Saba TM, et al. Cardiopulmonary hemodynamics after opsonic a-2 surface binding glycoprotein therapy in injured patients. Surgery 1979; 86: 284–93.

    PubMed  CAS  Google Scholar 

  33. Boughton BJ, Simpson A, Wharton C. Conformational charges and loss of opsonic function in frozen or heat-treated plasma fibronectin. Vox Sang 1984; 46: 254–9.

    Article  PubMed  CAS  Google Scholar 

  34. Mosher DF. Fibronectin. Prog Hemostasis and Thrombosis 1980; 5: 111–51.

    CAS  Google Scholar 

  35. Mosher DF, Grossman JE. Clinical use of fibronectin. La Ricerca Clin Lab 1983; 13: 43–54.

    CAS  Google Scholar 

  36. Furcht L. Structure and function of the adhesive glycoprotein fibronectin. Modern Cell Biol 1983; 1: 53–117.

    Google Scholar 

  37. Saba TM. Prevention of liver reticuloendothelial systemic host defense failure after surgery by intravenous opsonic glycoprotein therapy. Ann Surg 1978; 188: 142–52.

    Article  PubMed  CAS  Google Scholar 

  38. Saba TM, Blumenstock FA, Scovill WA, Bernard H. Cryoprecipitate reversal of opsonic a2 surface binding glycoprotein deficiency in septic surgical and trauma patients. Science 1978; 201: 622–4.

    Article  PubMed  CAS  Google Scholar 

  39. Gandhi JG, Van der Salm T, Szymanski 10. Effect of cardiopulmonary bypass on plasma fibronectin, IgG and C3. Transfusion 1983; 23: 476–9.

    Article  PubMed  CAS  Google Scholar 

  40. Brodin B, Berghem L, Friberg-Nielson S, Nordstrom H, Schildt B. Fibronectin in the treatment of septicemia — a preliminary report. In: 7th World Congress of Anesthesiology Hamburg, Excerpta Medica 1980: 504–5.

    Google Scholar 

  41. Lanser ME, Saba TM, Scovill WA. Opsonic glycoprotein (plasma fibronectin) levels after burn injury. Relationship to extent of burn and development of sepsis. Ann Surg 1980; 192: 776–82.

    Article  PubMed  CAS  Google Scholar 

  42. Dietch EA, Gelder F, McDonald JC. The relationship between CIg depletion and peripheral neutrophil function in rabbits and man. J Trauma 1982; 22: 469–75.

    Article  Google Scholar 

  43. Dietch EA, Gelder F, McDonald JC. Sequential prospective analysis of the nonspecific host defense system after thermal injury. Arch Surg 1984; 119: 83–9.

    Google Scholar 

  44. Richards WO, Scovill WA, Baekhyo S. Opsonic fibronectin deficiency in patients with intra-abdominal infection. Surgery 1983; 94: 210–7.

    PubMed  CAS  Google Scholar 

  45. Lanser ME, Saba TM. Correction of serum opsonic defects after burn and sepsis by opsonic fibronectin administration. Arch Surg 1983; 118: 338–42.

    PubMed  CAS  Google Scholar 

  46. Rubli E, Bussard S, Frei E, Lundsgaard-Hansen P. Pappova E. Plasma fibronectin and associated variables in surgical intensive care patients. Ann Surg 1983; 197: 310–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. L. Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank Groningen-Drenthe, Groningen, The Netherlands

    C. Th. Smit Sibinga  & P. C. Das  & 

  2. Red Cross Blood Transfusion Service Hessen, Frankfurt am Main, Germany

    S. Seidl

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Snyder, E.L. (1985). The Current of Status of Fibronectin in Clinical Medical Practice. In: Smit Sibinga, C.T., Das, P.C., Seidl, S. (eds) Plasma Fractionation and Blood Transfusion. Developments in Hematology and Immunology, vol 13. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2631-1_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2631-1_27

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9644-7

  • Online ISBN: 978-1-4613-2631-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation